39502-43-7

Upstream product

• 24652-66-2 2-fluorobenzaldehyde oxime 
• 24652-66-2 (E)-2-fluorobenzaldehyde oxime 
• 128-09-6 N-chloro-succinimide 
• 446-52-6 2-Fluorobenzaldehyde 

Downstream Products

• 1960-93-6 methyl-3-(2-fluorophenyl)-5-methylisoxazol-4-carboxylate 
• 139059-93-1 3-(2-fluorophenyl)-6-oxo-8,8-dimethyl-1-oxa-2,7-diazaspiro<4.4>non-2-ene 
• 931386-50-4 3-(2-fluorophenyl)-5-(3-(2-fluorophenyl)isoxazol-4-yl)-5-(trifluoromethyl)-[1,4,2]dioxazole 
• 943327-61-5 1-[3-(2-fluoro-phenyl)-5-methyl-isoxazol-4-yl]-ethanone 
• 1736-20-5 3-(2-fluorophenyl)-5-methylisoxazole-4-carboxylic acid 
• 1051372-04-3 methyl 3-(3-(2-fluorophenyl)isoxazol-5-yl)propanoate 
• 1312713-58-8 (3-(2-fluorophenyl)-8-isopropyl-1-oxa-2,7,8-triazaspiro[4.4]non-2-en-7-yl)(furan-2-yl)methanone 
• 1312713-53-3 (4-(tert-butyl)phenyl)(3-(2-fluorophenyl)-8-isopropyl-1-oxa-2,7,8-triazaspiro[4.4]non-2-en-7-yl)methanone 
• 1312713-62-4 1-(8-(4-chlorophenyl)-3-(2-fluorophenyl)-1-oxa-2,7,8-triazaspiro[4.4]non-2-en-7-yl)ethanone 
• 1312713-66-8 (3-(2-fluorophenyl)-8-methyl-1-oxa-2,7,8-triazaspiro[4.4]non-2-en-7-yl)(pyrazin-2-yl)methanone 
• 139060-01-8 2-Fluoro-benzonitrile N-oxide 
• 1246303-74-1 t-butyl 3-(2-fluorophenyl)-4-oxo-6,7-dihydroisoxazolo[4,5-c]pyridine-5(4H)-carboxylate 
• 1198800-30-4 3-(2-fluoro-phenyl)-isoxazole-5-sulfonic acid pentafluorophenyl ester 

Relevant academic research and scientific papers

Dibenzazepine-linked isoxazoles: New and potent class of α-glucosidase inhibitors

α-Glucosidase inhibition is a valid approach for controlling hyperglycemia in diabetes. In the current study, new molecules as a hybrid of isoxazole and dibenzazepine scaffolds were designed, based on their literature as antidiabetic agents. For this, a series of dibenzazepine-linked isoxazoles (33–54) was prepared using Nitrile oxide-Alkyne cycloaddition (NOAC) reaction, and evaluated for their α-glucosidase inhibitory activities to explore new hits for treatment of diabetes. Most of the compounds showed potent inhibitory potency against α-glucosidase (EC 3.2.1.20) enzyme (IC50 = 35.62 ± 1.48 to 333.30 ± 1.67 μM) using acarbose as a reference drug (IC50 = 875.75 ± 2.08 μM). Structure-activity relationship, kinetics and molecular docking studies of active isoxazoles were also determined to study enzyme-inhibitor interactions. Compounds 33, 40, 41, 46, 48–50, and 54 showed binding interactions with critical amino acid residues of α-glucosidase enzyme, such as Lys156, Ser157, Asp242, and Gln353.

Osthole isoxazoline derivative as well as preparation method and application thereof

The invention discloses an isoxazolinyl osthole derivative, a preparation method thereof and application of the isoxazolinyl sthole derivative as an insecticide. The chemical structure of the isoxazolinyl osthole derivative is shown as a general formula (

SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION

The present invention covers aminothiazole compounds of general formula (I) : in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing sa

Triazole alcohol derivative as well as preparation method and application thereof

The invention relates to a triazole alcohol derivative as well as a preparation method and application thereof. The chemical structure of the triazole alcohol derivative is shown as a formula I, R1 represents a benzene ring or a substituted benzene ring, and substituent groups of the substituted benzene ring can be located at all positions of the benzene ring, can be mono-substituted or multi-substituted, and can be selected from a) halogen which is F and Cl; b) an electron withdrawing group which is cyano or trifluoromethyl; c ) a lower alkyl of 1-4 carbon atoms or a halogen substituted loweralkyl; and d) lower alkoxy of 1-4 carbon atoms or halogen substituted lower alkoxy. The compound of the invention has strong antifungal activity, has the advantages of low toxicity, wide antibacterial spectrum and the like, and can be used for preparing antifungal drugs.

Design, synthesis, and in vitro evaluation of novel triazole analogues featuring isoxazole moieties as antifungal agents

In order to develop novel antifungal agents, based on our previous work, a series of (2R,3R)-3-((3-substitutied-isoxazol-5-yl)methoxy)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl) butan-2-ol (a1-a26) were designed and synthesized. All of the compounds exhibited good in vitro antifungal activities against eight human pathogenic fungi. Among them, compound a6 showed excellent inhibitory activity against Candida albicans and Candida parasilosis with MIC80 values of 0.0313 μg/mL. In addition, compounds a6, a9, a12, a13 and a14 exhibited moderate inhibitory activities against fluconazole-resistant isolates with MIC80 values ranging from 8 μg/mL to 16 μg/mL. Furthermore, compounds a6, a12 and a23 exhibited low inhibition profiles for CYP3A4. Clear SARs were analyzed, and the molecular docking experiment was carried out to further investigate the relationship between a6 and the target enzyme CYP51.

Discovery of Natural Product-Based Fungicides (II): Semisynthesis and Biological Activity of Sarisan Attached 3-Phenylisoxazolines as Antifungal Agents

Many phytopathogenic fungi cause severe damage to crop yields. In continuation of our research aimed at the discovery and development of natural products-based fungicides, a series of thirty-one sarisan attached 3-phenylisoxazolines were synthesized and evaluated for their antifungal activities against five phytopathogenic fungi (B. cinerea, C. lagenarium, A. solani, F. solani, and F. graminearum). Among all title sarisan derivatives, compounds IV2, IV14 and IV23 showed potent antifungal activity against some phytopathogenic fungi. In particular, compound IV2 exhibited a broad-spectrum and more potent antifungal activity against A. solani, F. solani, and F. graminearum than the commercial fungicide Hymexazol. In addition, compounds IV2, IV14 and IV23 also displayed relative low toxicity on normal NRK-52E cells. This work will give some insights into the development of sarisan derivatives as new fungicide candidates in plant protection.

Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis

Farnesoid X receptor (FXR) plays a key role in bile acid homeostasis, inflammation, fibrosis, and metabolism of lipid and glucose and becomes a promising therapeutic target for nonalcoholic steatohepatitis (NASH) or other FXR-dependent diseases. The phase III trial results of obeticholic acid demonstrate that the FXR agonists emerge as a promising intervention in patients with NASH and fibrosis, but this bile acid-derived FXR agonist brings severe pruritus and an elevated risk of cardiovascular disease for patients. Herein, we reported our efforts in the discovery of a series of non-bile acid FXR agonists, and 36 compounds were designed and synthesized based on the structure-based drug design and structural optimization strategies. Particularly, compound 42 is a highly potent and selective FXR agonist, along with good pharmacokinetic profiles, high liver distribution, and preferable in vivo efficacy, indicating that it is a potential candidate for the treatment of NASH or other FXR-dependent diseases.

Synthesis and biological evaluation of novel 1-(aryl-aldehyde-oxime)uracil derivatives as a new class of thymidine phosphorylase inhibitors

A novel series of 1-(aryl aldehyd oxime) uracil derivatives were synthesized, characterized and evaluated for its inhibitory activity against thymidine phosphorylase. Among them, the compound 8d, 8e, 8f, 8g and 8l displayed potent thymidine phosphorylase

PYRROLOPYRIMIDINES AS CFTR POTENTIATORS

The present invention relates to compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiator

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.